Caffeine for Premature Birth

(CARES-Pilot Trial)

This trial explores whether caffeine can help preterm infants who need breathing support leave the hospital sooner. Researchers aim to determine if they can recruit enough participants and if medical teams can adhere to the treatment plan. Babies born between 28 and 34 weeks who use breathing machines or oxygen qualify for this study. Participants will receive either caffeine or a placebo (a look-alike substance with no active medicine) once a day while they need breathing support. The goal is to determine if caffeine affects the time these infants spend in the NICU. As a Phase 2 trial, this research focuses on measuring caffeine's effectiveness in an initial, smaller group of infants.

The trial information does not specify whether participants must stop taking their current medications. Since the trial involves infants, it is likely that any medication changes would be managed by the medical team.

Research has shown that caffeine is generally safe for premature babies who need breathing assistance. The CAP trial found that caffeine treatment reduced the risk of bronchopulmonary dysplasia in very-low-birth-weight babies. Additionally, caffeine used in the amounts tested in the CAP trial showed no negative effects on movement skills up to middle school age.

Other studies have found that caffeine can improve several important outcomes for premature babies. It can shorten the time babies need on breathing machines and help them transition off this support more successfully. Furthermore, caffeine has been linked to better survival rates without developmental disabilities in these infants.

Caffeine citrate is unique because it offers a potential new approach to helping premature infants who need respiratory support. Unlike other treatments that might focus on mechanical ventilation or oxygen therapy, caffeine citrate works by stimulating the central nervous system, which can enhance the baby's ability to breathe independently. Researchers are excited about this treatment because caffeine is already well-known for its safety profile and widespread use in neonatal care, and it may lead to quicker weaning from respiratory support, reducing the risk of long-term complications associated with prolonged mechanical ventilation.

This trial will compare caffeine therapy with a placebo in preterm infants. Studies have shown that caffeine therapy lowers the risk of bronchopulmonary dysplasia in very-low-birth-weight babies. It also improves survival rates and reduces the chances of cerebral palsy and movement problems. Caffeine supports better brain development and helps preterm babies breathe more easily, potentially shortening their time on breathing machines. By reducing stress and inflammation, caffeine may protect against long-term brain damage. Overall, caffeine effectively supports the health of preterm infants.¹²⁶⁷⁸